{"cluster": 45, "subcluster": 8, "abstract_summ": "In conclusion, COVID-19 patients with acute respiratory failure present a severe hypercoagulability rather than consumptive coagulopathy.Importantly however, Caucasian COVID19 patients on low molecular weight heparin thromboprophylaxis rarely develop overt disseminated intravascular coagulation (DIC).Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC).Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients.Thromboembolic events are recognised complications of viral infection, but the diagnosis of an acute pulmonary thrombotic complication in the context of coronavirus disease 2019 (COVID-19) can be challenging because of the similarities of presentation, logistical considerations of diagnosis in a patient isolated for infection control reasons and the effects of cognitive errors in diagnostic reasoning.", "title_summ": "D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue?Coagulation dysfunction: A hallmark in COVID-19.COVID19 coagulopathy in Caucasian patientsCOVID-19 and its implications for thrombosis and anticoagulationThrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow\u2019s triadCOVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory FailureThromboinflammation in COVID-19 acute lung injuryCOVID-19-associated coagulopathy: An exploration of mechanismsHypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New ChallengeThe hypercoagulable state in COVID-19: Incidence, pathophysiology, and managementHemostatic laboratory derangements in COVID-19 with a focus on platelet count.COVID-19 and coagulative axis: review of emerging aspects in a novel disease.", "title_abstract_phrases": "In conclusion, COVID-19 patients with acute respiratory failure present a severe hypercoagulability rather than consumptive coagulopathy.COVID-19 and its implications for thrombosis and anticoagulationSevere acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC).Importantly however, Caucasian COVID19 patients on low molecular weight heparin thromboprophylaxis rarely develop overt disseminated intravascular coagulation (DIC).Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients.Thromboembolic events are recognised complications of viral infection, but the diagnosis of an acute pulmonary thrombotic complication in the context of coronavirus disease 2019 (COVID-19) can be challenging because of the similarities of presentation, logistical considerations of diagnosis in a patient isolated for infection control reasons and the effects of cognitive errors in diagnostic reasoning."}